Is Afamelanotide Legit? Evidence Grade and Plain-English Verdict
Afamelanotide is rated Level A. The short verdict: Afamelanotide (Scenesse) is FDA-approved for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP) - a rare, severely debilitating condition. The Phase 3 evidence in EPP is solid and the approval is well-founded. Outside EPP, evidence for vitiligo is emerging in Phase 2. This is a legitimate, approved therapeutic for its specific indication.
Direct Answer
Afamelanotide (Scenesse) is FDA-approved for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP) - a rare, severely debilitating condition. The Phase 3 evidence in EPP is solid and the approval is well-founded. Outside EPP, evidence for vitiligo is emerging in Phase 2. This is a legitimate, approved therapeutic for its specific indication.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Skin & Beauty
- Best for
- Erythropoietic protoporphyria (EPP) phototoxicity prevention, vitiligo (investigational), melanocortin research
Why the Claim Is Strong or Weak
Afamelanotide (Melanotan I) is a synthetic analog of alpha-MSH that selectively activates MC1R to increase eumelanin production. It is FDA-approved for the treatment of erythropoietic protoporphyria (EPP), a rare genetic photosensitivity disorder.
As of April 2026, 3 new paper(s) published in PubMed including: New and currently investigated pharmacotherapies for the erythropoietic protoporphyrias: spotlight on dersimelagon and bitopertin; Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients.
Top Evidence Signals
- EPP Phototoxicity Reduction: Level A, includes human evidence - Langendonk et al. (2015, N Engl J Med, PASS study, n=94) showed afamelanotide 16 mg SC implant increased median pain-free sun exposure from 10 min to 70 min in EPP patients (p<0.001). FDA approved Scenesse in 2019 based on this and the CUV039 Phase III trial confirming reduced phototoxicity severity.
- Skin Pigmentation: Level A, includes human evidence - Consistent increases in melanin density and visible skin darkening documented across multiple controlled trials. Effect persists for weeks after implant insertion.
- Photoprotection: Level B, includes human evidence - Studies in healthy volunteers and photosensitive patients show increased minimal erythema dose (MED) and reduced sunburn response following treatment.
Where Claims Usually Overreach
- Regular skin and mole examinations recommended during treatment
- Not studied in patients with active melanoma or high melanoma risk
- Liver function should be monitored in EPP patients
- Use only for confirmed EPP diagnosis
Primary Sources
- Afamelanotide for erythropoietic protoporphyria. New England Journal of Medicine, 2015.
- Phase III trial of afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. British Journal of Dermatology, 2015.
- Long-term safety of afamelanotide in patients with erythropoietic protoporphyria. British Journal of Dermatology, 2022.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | EPP Phototoxicity Reduction (Level A), Skin Pigmentation (Level A), and Photoprotection (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Is Afamelanotide Legit? Evidence Grade and Plain-English Verdict." Last reviewed 2026-04-04. https://examinepeptides.com/answers/is-melanotan-i-legit/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.